Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
View/ Open
Author
Wang, Aoli
Yan, Xiao-E
Wu, Hong
Wang, Wenchao
Hu, Chen
Chen, Cheng
Zhao, Zheng
Zhao, Peng
Li, Xixiang
Wang, Li
Wang, Beilei
Ye, Zi
Wang, Chu
Zhang, Wei
Chen, Liang
Liu, Jing
Yun, Cai-Hong
Liu, Qingsong
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.18632/oncotarget.11951Metadata
Show full item recordCitation
Wang, A., X. Yan, H. Wu, W. Wang, C. Hu, C. Chen, Z. Zhao, et al. 2016. “Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.” Oncotarget 7 (43): 69760-69769. doi:10.18632/oncotarget.11951. http://dx.doi.org/10.18632/oncotarget.11951.Abstract
Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/mutant engineered isogenic BaF3 cell lines we confirmed the irreversible binding mode of Ibrutinib with EGFR wt/mutant kinase via Cys797. However, comparing to typical irreversible EGFR inhibitor, such as WZ4002, the washing-out experiments revealed a much less efficient covalent binding for Ibrutinib. The biochemical binding affinity examination in the EGFR L858R/T790M kinase revealed that, comparing to more efficient irreversible inhibitor WZ4002 (Kd: 0.074 μM), Ibrutinib exhibited less efficient binding (Kd: 0.18 μM). An X-ray crystal structure of EGFR (T790M) in complex with Ibrutinib exhibited a unique DFG-in/c-Helix-out inactive binding conformation, which partially explained the less efficiency of covalent binding and provided insight for further development of highly efficient irreversible binding inhibitor for the EGFR mutant kinase. These results also imply that, unlike the canonical irreversible inhibitor, sustained effective concentration might be required for Ibrutinib in order to achieve the maximal efficacy in the clinic application against EGFR driven NSCLC.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342513/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072107
Collections
- FAS Scholarly Articles [18292]
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)